Related Experiment Videos
Phase II trial of topotecan in patients with advanced renal cell carcinoma
T M Law1, D H Ilson, R J Motzer
1Department of Medicine, Memorial Sloan-Kettering Cancer Center, New York, NY.
Investigational New Drugs
|January 1, 1994
Abstract:
Fifteen patients with advanced renal cell carcinoma were treated on a phase II trial with topotecan. None of the fourteen evaluable patients achieved a complete or partial response. Myelosuppression was the most common toxicity. Eighty percent (12 of 15) of patients experienced grade III or IV neutropenia and/or anemia. Topotecan is not efficacious in the treatment of advanced renal cell carcinoma.